News Reel
2902, 2024
Cholangiocarcinoma Foundation Australia Partners with Genomic Focus
A New Bridge and Access That Helps Better Equip and Empower the Cholangiocarcinoma Patient's Capacity to More Effectively Respond
2908, 2023
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia
PBAC endorses IMFINZI (durvalumab) for advanced biliary tract cancer in Australia. First new treatment in 10+ years, boosting survival rates.
2807, 2018
Vyriad Expands Phase 1 Trial to Test Voyager-V1
Vyriad is expanding its ongoing Phase 1 clinical trial [...]
